Literature DB >> 15009309

Cutaneous necrosis induced by acenocoumarol.

M Valdivielso1, I Longo, M Lecona, P Lázaro.   

Abstract

Cutaneous necrosis is an infrequent but well-documented complication of oral anticoagulants. In the pathogenesis of cutaneous necrosis induced by oral anticoagulants recent hypotheses favour the combined role of local factors and a transient unbalance of coagulation mechanisms leading to an hypercoagulable state. There exists a genetic factor that determines a decreased level of two vitamin-K dependent glycoproteins, namely protein C and protein S. We present the case of an obese woman that developed an extensive cutaneous necrosis while receiving acenocoumarol for a deep venous thrombosis. She had an heterozygous deficit for protein C. The histopathologic findings of vessel thrombi and red blood cell extravasation were consistent with the clinical picture. A biopsy specimen taken from an initial lesion disclosed images of leucocytoclastic vasculitis. We reviewed the literature focusing on the pathogenesis and the histopathology of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009309     DOI: 10.1111/j.1468-3083.2004.00735.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  3 in total

1.  Skin Necrosis Induced by Coumarin Congeners.

Authors:  Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2017-08-01

2.  Successful catheter directed thrombolysis in postpartum deep venous thrombosis complicated by nicoumalone-induced skin necrosis and failure in retrieval of inferior vena caval filter.

Authors:  B C Srinivas; Soumya Patra; Navin Agrawal; C N Manjunath
Journal:  BMJ Case Rep       Date:  2013-07-25

3.  [Impending Coumarin-necrosis in a patient with heterozygous protein C deficiency type I].

Authors:  R Schulze; W Behr; H Wittwer; S Harwix; K Murmann; W V Scheidt; W Ehret; G Schlimok
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.